

Research Grade Varlilumab

Summary

Catalog No.	DHD72201
Alternative Names	1F5, CDX-1127, CAS: 1393344-72-3
Clone ID	Varlilumab
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	2 mg/ml
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1-kappa
Applications	Research Grade Biosimilar
Target	CD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Accession	P26842

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


Note

For research use only. Not suitable for clinical or therapeutic use.

Description

Varlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.

Data Image




SDS PAGE for Varlilumab

SDS-PAGE



Recombinant Proteins & Antibodies



The purity of this product is >95% as determined by SEC-HPLC.

SEC-HPLC